Table 1 TE infection events by grade and treatment arm in the safety population of the FIRST trial (1613 patients, including 532, 540, and 541 in the Rd continuous, Rd18, and MPT arms, respectively)

From: A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

TE infection events, na

Grade 1 (mild) infections

Grade 2 (moderate) infections

Grade 3 (severe) infections

Grade 4 (life-threatening) infections

Grade 5 (death) infections

Unknown grade infections

 

Rd cont

Rd18

MPT

Total

Rd cont

Rd18

MPT

Total

Rd cont

Rd18

MPT

Total

Rd cont

Rd18

MPT

Total

Rd cont

Rd18

MPT

Total

Rd cont

Rd18

MPT

Total

Events in the first 4 months

134

136

85

355

157

170

114

441

57

68

62

187

17

16

15

48

11

10

9

30

0

3

0

3

Events in the first 18 months

339

356

190

885

440

422

307

1169

148

145

105

398

35

27

24

86

20

20

15

55

0

3

2

5

Events beyond 18 months

175

4

4

183

174

3

1

178

62

1

0

63

6

0

0

6

2

0

0

2

1

0

0

1

Total

514

360

194

1068

614

425

308

1347

210

146

105

461

41

27

24

92

22

20

15

57

1

3

2

6

  1. MPT melphalan, prednisone, and thalidomide, Rd cont lenalidomide plus low-dose dexamethasone until disease progression, Rd18 lenalidomide plus low-dose dexamethasone for 18 cycles, TE treatment emergent
  2. aA total of 79 infections occurred before the first treatment administration, and 15 infections occurred > 28 days after treatment discontinuation